摘要
本文采用双抗夹心ELISA法对99例消化系恶性肿瘤、10例良性肿瘤和40例正常对照组进行血清sIL-2R测定。结果显示恶性肿瘤组血清sIL-2R明显增高,与良性肿瘤组和正常对照组相比有显著差异(P<0.001),但不同类型恶性肿瘤之间血清sIL-2R无差异(P>0.05)。11例胃癌病人行根治术后血清sIL-2R显著降低(P<0.01)。提示血清sIL-2R测定有助于观察消化系恶性肿瘤的疗效、判断预后,并可望成为一种新的消化系恶性肿瘤标记物。
AIMS To evaluate the variance of sIL-2R in serum in cancer of digestive system. METHODS Using ELISA method to determine the sIL-2R in serum in 99 patients with cancer, 10 patients with innocent neoplasm and 40 normal controls. RESULTS The sIL-2R in serum in cancer increased significantly,and there were signigicant difference compared with the inno-cent neoplasm and the controls (P<0. 001). But there were no the difference between different type of cancer(P>0. 05). And it decreases significantly in 11 patients whose stomach carcinoma have been operated(P<0. 01). CONCLUSIONS Determining the slL-2R in serum helps to observe the curative effect and its prognosis in cancer of digestive system. It may be a new label of can-cer of digestive system in the future.
出处
《临床肿瘤学杂志》
CAS
1996年第3期12-14,共3页
Chinese Clinical Oncology
